Gastrointestinal bleed · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review
FVC (% predicted) Change from baseline · people with bronchiectasis
1 finding from 1 review
Worse or unimproved within 5 weeks from randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH probably leads to lower worse or unimproved within 5 weeks from randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Mean disability (EDSS) score—at 1 week after randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH showed no clear difference in mean disability (EDSS) score—at 1 week after randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Participants with new exacerbations during · multiple sclerosis patients with acute exacerbations
It is very uncertain whether corticosteroids or ACTH changes participants with new exacerbations during compared with placebo (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with radicular low back pain (not due to spinal stenosis)
1 finding from 1 review
Function (continuous) RDQ‐18 (scale 0–18) · people with non‐radicular low back pain
1 finding from 1 review
Function (dichotomous) RDQ‐18 = 0 · people with non‐radicular low back pain
Systemic corticosteroids showed no clear difference in function (dichotomous) RDQ‐18 = 0 compared with placebo (low certainty).
1 finding from 1 review
Surgery Number of participants who underwent surgery · people with non‐radicular low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who experienced a serious adverse event · people with non‐radicular low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who experienced any adverse event Adverse event regardless of severity · people with non‐radicular low back pain
Systemic corticosteroids may leads to lower participants who experienced any adverse event Adverse event… compared with placebo (low certainty).
1 finding from 1 review